Notification pursuant to Section 8 para. 1 sentence 6 of the German Securities Prospectus Act (*Wertpapierprospektgesetz*)

Epigenomics AG announces pursuant to Section 8 para. 1 sentence 6 of the German Securities Prospectus Act (*Wertpapierprospektgesetz, WpPG*) that in connection with the offering

12,007,180 shares

are being placed at the subscription price of EUR 1.86 per share.

The issue volume was announced on October 23, 2018, by way of an ad hoc release of Epigenomics AG and its publication will be available on the website of Epigenomics AG on the same date under http://www.epigenomics.com/news-investors/capital-increase/ pursuant to Sections 8 para. 1 sentence 6, 14 para. 2 sentence 1 number 3 lit. a) WpPG and printed copies will be available for distribution free-of-charge at the issuer pursuant to Sections 8 para. 1 sentence 6, 14 para. 2 sentence 1 number 2 lit. b) WpPG.

Berlin, October 23, 2018

Epigenomics AG

The Executive Board

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN AND AUSTRALIA.

Important Notice

This publication does, in particular, not constitute an offer to sell or a solicitation of an offer to purchase any securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the laws of any state within the U.S., and may not be offered or sold in the United States or to or for the account or benefit of U.S. persons, except that the offered shares may be offered or sold to qualified institutional buyers in reliance on certain exemptions from the registration requirements of the Securities Act and applicable state securities laws. This publication and the 2 information contained herein may not be distributed or sent into the United States, or in any other jurisdiction in which offers or sales of the securities described herein would be prohibited by applicable laws and should not be distributed to United States persons or publications with a general circulation in the United States. No public offering of the shares is being made in the United States.

Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or *citizen of Australia, Canada or Japan. The securities referred to herein have not been and will not be registered under the applicable securities laws of Australia, Canada or Japan.*